Company intelligence / Profile preview
Lycia Therapeutics
South San Francisco, California, United Stateslyciatx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lycia has developed a proprietary LYTAC platform for targeted degradation of extracellular and membrane-bound disease-causing proteins. The company has advanced several programs toward the clinic, with lead candidates focused on autoimmune and inflammatory diseases. As of May 2024, the company completed a $106.6M Series C financing to support advancement into clinical trials.
- Therapeutic areas
- OtherImmunologyNeurology
- Modalities
- LYTACs (Lysosomal Targeting Chimeras)Protein degradersPotentially other biologic modalities (platform adaptable)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Eli Lilly & Company (multi-year research collaboration for up to five targets in immunology/pain)
Beyond the preview
Go deeper on Lycia Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lycia Therapeutics.